Total NDA/BLA, New Use Approvals Recovered As NMEs Slowed – CDER Report
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The declining trend in approval of new molecular entities has not been replicated in reviews of follow-on compounds, new formulations, and new uses, CDER's 2005 Report to the Nation suggests